{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:46:47Z","timestamp":1795034807619,"version":"4.10.2"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA0909900"],"award-info":[{"award-number":["2021YFA0909900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073770"],"award-info":[{"award-number":["82073770"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102751","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T04:02:08Z","timestamp":1761364928000},"page":"102751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Design of bifunctional RNA-binding compounds that can modulate siRNA hydrophobicity for deep penetration and gene silencing in the retina"],"prefix":"10.1016","volume":"36","author":[{"given":"Qi","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-8263","authenticated-orcid":false,"given":"Wanyi","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102751_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omtn.2025.102751_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0002-9440(10)64525-7","article-title":"Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization","volume":"157","author":"Spilsbury","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2025.102751_bib3","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41433-021-01766-w","article-title":"An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma","volume":"36","author":"Ghanchi","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.omtn.2025.102751_bib4","unstructured":"Gotadki, R. Anti-VEGF Market Research Report Information by Product (Eylea, Lucentis, and Beovu), by Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, and Age-Related Macular Degeneration) and by Region (North America, Europe, Asia-Pacific, And Rest Of The World) \u2013 Industry Forecast Till 2034, 2025. Report MRFR\/HC\/20363-HCR."},{"key":"10.1016\/j.omtn.2025.102751_bib5","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1021\/acs.molpharmaceut.0c01218","article-title":"Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats","volume":"18","author":"Jakubiak","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2025.102751_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.omtn.2025.102751_bib7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102751_bib8","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s13346-021-01043-z","article-title":"In vitro dissolution testing models of ocular implants for posterior segment drug delivery","volume":"12","author":"Adrianto","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.omtn.2025.102751_bib9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bph.12330","article-title":"Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy","volume":"170","author":"Guzman-Aranguez","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102751_bib10","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/jama.2023.4570","article-title":"siRNAs\u2014A New Class of Medicines","volume":"329","author":"Khvorova","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102751_bib11","doi-asserted-by":"crossref","first-page":"A4135443","DOI":"10.1161\/circ.150.suppl_1.4135443","article-title":"A Phase 1, Single Ascending Dose Study to Evaluate ALN-TTRsc04, a Next-Generation RNA Interference Therapeutic, in Healthy Participants for Potential Treatment of Transthyretin Amyloidosis","volume":"150","author":"Murad","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102751_bib12","first-page":"210","article-title":"Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model","volume":"9","author":"Reich","year":"2003","journal-title":"Mol. Vis."},{"key":"10.1016\/j.omtn.2025.102751_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.gt.3302641","article-title":"Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1","volume":"13","author":"Shen","year":"2006","journal-title":"Gene. Ther."},{"key":"10.1016\/j.omtn.2025.102751_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajo.2010.02.006","article-title":"RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027","volume":"150","author":"Kaiser","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtn.2025.102751_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4137\/OED.S4878","article-title":"Bevasiranib for the treatment of wet, age-related macular degeneration","volume":"2","author":"Garba","year":"2010","journal-title":"Ophthalmol. Eye Dis."},{"key":"10.1016\/j.omtn.2025.102751_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2019.06.022","article-title":"Chemical modulation of siRNA lipophilicity for efficient delivery","volume":"307","author":"Tai","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omtn.2025.102751_bib17","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1093\/nar\/gkr1002","article-title":"Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group","volume":"40","author":"Petrova","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102751_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/nar\/gkw1005","article-title":"Visualization of self-delivering hydrophobically modified siRNA cellular internalization","volume":"45","author":"Ly","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102751_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102088","article-title":"Single intravitreal administration of a tetravalent siRNA exhibits robust and efficient gene silencing in mouse and pig photoreceptors","volume":"35","author":"Cheng","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102751_bib20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/jop.2013.0148","article-title":"Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye","volume":"29","author":"Byrne","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2025.102751_bib21","doi-asserted-by":"crossref","first-page":"AB273","DOI":"10.1016\/j.jaad.2015.02.1092","article-title":"Update on phase 2 clinical trial results of RXI-109 treatment to reduce the formation of hypertrophic dermal scars","volume":"72","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.omtn.2025.102751_bib22","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.biomaterials.2018.02.007","article-title":"Noncovalent tagging of siRNA with steroids for transmembrane delivery","volume":"178","author":"Tai","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102751_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-811X-9-13","article-title":"Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers","volume":"9","author":"Ehsanian","year":"2011","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.omtn.2025.102751_bib24","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1021\/ja035117c","article-title":"Aminoglycoside (neomycin) preference is for A-form nucleic acids, not just RNA: results from a competition dialysis study","volume":"125","author":"Arya","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2025.102751_bib25","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1039\/C5SC01969A","article-title":"Potent inhibition of miR-27a by neomycin-bisbenzimidazole conjugates","volume":"6","author":"Nahar","year":"2015","journal-title":"Chem. Sci."},{"key":"10.1016\/j.omtn.2025.102751_bib26","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.jmedchem.8b00686","article-title":"Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs","volume":"62","author":"Shultz","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102751_bib27","first-page":"408","article-title":"The Role of Cholesterol in Membrane Fluidity and Stability","volume":"14","author":"Ahmed","year":"2024","journal-title":"J. Membr. Sci. Technol."},{"key":"10.1016\/j.omtn.2025.102751_bib28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/nar\/gku1362","article-title":"Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates","volume":"43","author":"Cuellar","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102751_bib29","doi-asserted-by":"crossref","first-page":"7984","DOI":"10.1093\/nar\/gkv762","article-title":"Identification of siRNA delivery enhancers by a chemical library screen","volume":"43","author":"Gilleron","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102751_bib30","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.1016\/j.biomaterials.2012.08.057","article-title":"A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy","volume":"33","author":"Ding","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102751_bib31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/mt.2008.298","article-title":"Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects","volume":"17","author":"Chang","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102751_bib32","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2025.102751_bib33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102751_bib34","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/jm049167j","article-title":"Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA","volume":"48","author":"Allerson","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102751_bib35","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1002\/anie.201006519","article-title":"Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs","volume":"50","author":"Manoharan","year":"2011","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.omtn.2025.102751_bib36","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"siRNA function in RNAi: a chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"RNA (New York, N.Y.)"},{"key":"10.1016\/j.omtn.2025.102751_bib37","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layzer","year":"2004","journal-title":"RNA (New York, N.Y.)"},{"key":"10.1016\/j.omtn.2025.102751_bib38","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/nar\/gkq846","article-title":"A role for human Dicer in pre-RISC loading of siRNAs","volume":"39","author":"Sakurai","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102751_bib39","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1021\/acs.molpharmaceut.9b00679","article-title":"Intravitreal Pharmacokinetics in Mice: SPECT\/CT Imaging and Scaling to Rabbits and Humans","volume":"16","author":"Schmitt","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2025.102751_bib40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijpharm.2014.10.062","article-title":"High-throughput in vitro drug release and pharmacokinetic simulation as a tool for drug delivery system development: Application to intravitreal ocular administration","volume":"477","author":"Sarkhel","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtn.2025.102751_bib41","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/nar\/gky1232","article-title":"Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways","volume":"47","author":"Osborn","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102751_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067265","article-title":"Retinal Thickness Normative Data in Wild-Type Mice Using Customized Miniature SD-OCT","volume":"8","author":"Ferguson","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102751_bib43","doi-asserted-by":"crossref","first-page":"10447","DOI":"10.1093\/nar\/gkae686","article-title":"Efficacy, biodistribution and safety comparison of chemically modified antisense oligonucleotides in the retina","volume":"52","author":"V\u00e1zquez-Dom\u00ednguez","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102751_bib44","series-title":"2024 ARVO Annual Meeting Abstract","first-page":"5305","article-title":"PYC-001: A Promising RNA Therapeutic for Autosomal Dominant Optic Atrophy","author":"Grainok","year":"2024"},{"key":"10.1016\/j.omtn.2025.102751_bib45","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/bjo.2004.059089","article-title":"Generation of transgenic mice with mild and severe retinal neovascularisation","volume":"89","author":"Lai","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.omtn.2025.102751_bib46","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1021\/mp0700209","article-title":"The Rule of Five Revisited: Applying Log D in Place of Log P in Drug-Likeness Filters","volume":"4","author":"Bhal","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2025.102751_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102522","article-title":"Design and screening of novel endosomal escape compounds that enhance functional delivery of oligonucleotides in vitro","volume":"36","author":"Estupi\u00f1\u00e1n","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102751_bib48","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotech."},{"key":"10.1016\/j.omtn.2025.102751_bib49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jconrel.2016.04.013","article-title":"An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing","volume":"232","author":"Bienk","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omtn.2025.102751_bib50","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.bmcl.2004.07.018","article-title":"Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells","volume":"14","author":"Lorenz","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.omtn.2025.102751_bib51","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1021\/acs.jmedchem.4c01330","article-title":"RNA-Binding Small Molecules in Drug Discovery and Delivery: An Overview from Fundamentals","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102751_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1606","article-title":"Insight into the siRNA transmembrane delivery-From cholesterol conjugating to tagging","volume":"12","author":"Zheng","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.omtn.2025.102751_bib53","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102751_bib54","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA (New York, N.Y.)"},{"key":"10.1016\/j.omtn.2025.102751_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb0310","article-title":"Cytosolic delivery of proteins by cholesterol tagging","volume":"6","author":"Tai","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102751_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600261","article-title":"Direct proof of spontaneous translocation of lipid-covered hydrophobic nanoparticles through a phospholipid bilayer","volume":"2","author":"Guo","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102751_bib57","doi-asserted-by":"crossref","first-page":"14396","DOI":"10.1021\/jacs.7b06597","article-title":"Cytosolic Delivery of Proteins by Bioreversible Esterification","volume":"139","author":"Mix","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2025.102751_bib58","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1021\/jacs.8b10947","article-title":"Cytosolic Delivery of Proteins Using Amphiphilic Polymers with 2-Pyridinecarboxaldehyde Groups for Site-Selective Attachment","volume":"141","author":"Sangsuwan","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2025.102751_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.5582\/bst.2023.01285","article-title":"Development of a novel cholesterol tag-based system for trans-membrane transport of protein drugs","volume":"17","author":"Zhao","year":"2024","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.omtn.2025.102751_bib60","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1111\/cts.13412","article-title":"Pharmacokinetic evaluation of radiolabeled intraocular anti-CLEC14a antibody in preclinical animal species and application in humans","volume":"15","author":"Park","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.omtn.2025.102751_bib61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","article-title":"Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data","volume":"137","author":"Del Amo","year":"2015","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtn.2025.102751_bib62","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1089\/nat.2014.0489","article-title":"Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection","volume":"24","author":"Solano","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2025.102751_bib63","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omtn.2025.102751_bib64","doi-asserted-by":"crossref","first-page":"10934","DOI":"10.1021\/acs.jmedchem.3c00881","article-title":"Design of Tracers in Fluorescence Polarization Assay for Extensive Application in Small Molecule Drug Discovery","volume":"66","author":"Hua","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102751_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gni178","article-title":"Real-time quantification of microRNAs by stem-loop RT-PCR","volume":"33","author":"Chen","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102751_bib66","doi-asserted-by":"crossref","DOI":"10.1093\/biomethods\/bpae029","article-title":"A highly sensitive stem-loop RT-qPCR method to study siRNA intracellular pharmacokinetics and pharmacodynamics","volume":"9","author":"Chen","year":"2024","journal-title":"Biol. Methods Protoc."},{"key":"10.1016\/j.omtn.2025.102751_bib67","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3559","article-title":"Optic Nerve Crush in Mice to Study Retinal Ganglion Cell Survival and Regeneration","volume":"10","author":"Cameron","year":"2020","journal-title":"Bio. Protoc."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T02:05:19Z","timestamp":1766196319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125003051"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102751","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of bifunctional RNA-binding compounds that can modulate siRNA hydrophobicity for deep penetration and gene silencing in the retina","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102751"}}